Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892023874> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2892023874 abstract "TPS7573 Background: The PD-1/PD-L1 pathway is an important immune checkpoint used by tumor cells and may provide an effective target for enhancing anticancer immune response. In DLBCL, high PD-L1 expression has been identified as a negative prognostic factor for overall survival. Durvalumab (MEDI4736) is a high-affinity human IgG1 monoclonal Ab that selectively blocks PD-L1 binding to PD-1 and CD80, and preliminary preclinical and clinical activity support the study of durvalumab in high-risk DLBCL subtypes. The primary study objective is to explore the clinical activity of durvalumab with R-CHOP in non-activated B-cell–like (non-ABC) and durvalumab with lenalidomide + R-CHOP (R 2 -CHOP) in ABC previously untreated DLBCL; secondary objectives are to evaluate safety and identify biomarkers predictive of clinical response. Methods: This is a phase II, two-arm, open-label, global, multicenter study of durvalumab combinations in patients with previously untreated, high-risk DLBCL (MEDI4736-DLBCL-001; EUDRA CT 2015-005173-20; NCT03003520). High risk was defined as Ann Arbor stage III/IV or II with bulky disease (≥7.0 cm), along with intermediate-high/high IPI ≥3 or NCCN-IPI ≥4; patients must also have CD20+ DLBCL, ECOG PS 0-2, and no prior antilymphoma therapy. All patients receive durvalumab + R-CHOP21 in induction cycle 1 simultaneous to cell-of-origin (COO) analysis by gene expression profiling with NanoString technology. Beginning with cycle 2, Arm A (non-ABC) receives durvalumab 1125 mg IV on day 1 with 6 or 8 cycles of R-CHOP21; Arm B (ABC) receives the same durvalumab + R-CHOP21 doses with oral lenalidomide 15 mg/day on days 1-14. Both arms receive durvalumab consolidation 1500 mg IV on day 1 q28d for ≤12 months from induction cycle 1, day 1. The primary endpoint is 2-y progression-free survival (PFS); secondary endpoints include clinical response to treatment in biomarker-defined subpopulations (tumor and peripheral blood) and safety as assessed per NCI CTCAE v4.03 criteria. Exploratory endpoints include PFS at 12 mo, complete response, and PK/PD. Recruitment is ongoing, with a target enrollment of 120 patients. Clinical trial information: NCT03003520." @default.
- W2892023874 created "2018-09-27" @default.
- W2892023874 creator A5014125875 @default.
- W2892023874 creator A5034222353 @default.
- W2892023874 creator A5036867361 @default.
- W2892023874 creator A5045870812 @default.
- W2892023874 creator A5047383980 @default.
- W2892023874 creator A5061713890 @default.
- W2892023874 creator A5068401531 @default.
- W2892023874 creator A5071715168 @default.
- W2892023874 date "2017-05-20" @default.
- W2892023874 modified "2023-09-28" @default.
- W2892023874 title "Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma." @default.
- W2892023874 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps7573" @default.
- W2892023874 hasPublicationYear "2017" @default.
- W2892023874 type Work @default.
- W2892023874 sameAs 2892023874 @default.
- W2892023874 citedByCount "0" @default.
- W2892023874 crossrefType "journal-article" @default.
- W2892023874 hasAuthorship W2892023874A5014125875 @default.
- W2892023874 hasAuthorship W2892023874A5034222353 @default.
- W2892023874 hasAuthorship W2892023874A5036867361 @default.
- W2892023874 hasAuthorship W2892023874A5045870812 @default.
- W2892023874 hasAuthorship W2892023874A5047383980 @default.
- W2892023874 hasAuthorship W2892023874A5061713890 @default.
- W2892023874 hasAuthorship W2892023874A5068401531 @default.
- W2892023874 hasAuthorship W2892023874A5071715168 @default.
- W2892023874 hasConcept C121608353 @default.
- W2892023874 hasConcept C126322002 @default.
- W2892023874 hasConcept C143998085 @default.
- W2892023874 hasConcept C159654299 @default.
- W2892023874 hasConcept C203014093 @default.
- W2892023874 hasConcept C2776063141 @default.
- W2892023874 hasConcept C2776364478 @default.
- W2892023874 hasConcept C2777701055 @default.
- W2892023874 hasConcept C2777742743 @default.
- W2892023874 hasConcept C2778559949 @default.
- W2892023874 hasConcept C2779338263 @default.
- W2892023874 hasConcept C2779725641 @default.
- W2892023874 hasConcept C2780030458 @default.
- W2892023874 hasConcept C502942594 @default.
- W2892023874 hasConcept C71924100 @default.
- W2892023874 hasConceptScore W2892023874C121608353 @default.
- W2892023874 hasConceptScore W2892023874C126322002 @default.
- W2892023874 hasConceptScore W2892023874C143998085 @default.
- W2892023874 hasConceptScore W2892023874C159654299 @default.
- W2892023874 hasConceptScore W2892023874C203014093 @default.
- W2892023874 hasConceptScore W2892023874C2776063141 @default.
- W2892023874 hasConceptScore W2892023874C2776364478 @default.
- W2892023874 hasConceptScore W2892023874C2777701055 @default.
- W2892023874 hasConceptScore W2892023874C2777742743 @default.
- W2892023874 hasConceptScore W2892023874C2778559949 @default.
- W2892023874 hasConceptScore W2892023874C2779338263 @default.
- W2892023874 hasConceptScore W2892023874C2779725641 @default.
- W2892023874 hasConceptScore W2892023874C2780030458 @default.
- W2892023874 hasConceptScore W2892023874C502942594 @default.
- W2892023874 hasConceptScore W2892023874C71924100 @default.
- W2892023874 hasLocation W28920238741 @default.
- W2892023874 hasOpenAccess W2892023874 @default.
- W2892023874 hasPrimaryLocation W28920238741 @default.
- W2892023874 hasRelatedWork W2410070419 @default.
- W2892023874 hasRelatedWork W2509642163 @default.
- W2892023874 hasRelatedWork W2521558636 @default.
- W2892023874 hasRelatedWork W2566602522 @default.
- W2892023874 hasRelatedWork W2583522154 @default.
- W2892023874 hasRelatedWork W2622805445 @default.
- W2892023874 hasRelatedWork W2741825615 @default.
- W2892023874 hasRelatedWork W2741978170 @default.
- W2892023874 hasRelatedWork W2757788013 @default.
- W2892023874 hasRelatedWork W2785259311 @default.
- W2892023874 hasRelatedWork W2890542895 @default.
- W2892023874 hasRelatedWork W2903627239 @default.
- W2892023874 hasRelatedWork W2907239506 @default.
- W2892023874 hasRelatedWork W2912240505 @default.
- W2892023874 hasRelatedWork W2914285194 @default.
- W2892023874 hasRelatedWork W2953683577 @default.
- W2892023874 hasRelatedWork W2979686317 @default.
- W2892023874 hasRelatedWork W2983979814 @default.
- W2892023874 hasRelatedWork W3014531645 @default.
- W2892023874 hasRelatedWork W3119901632 @default.
- W2892023874 isParatext "false" @default.
- W2892023874 isRetracted "false" @default.
- W2892023874 magId "2892023874" @default.
- W2892023874 workType "article" @default.